Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Adicet Bio Inc (ACET)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$2.92-5.81%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for ACET yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Maintain capital to fund operations into second half of 2027 | The company plans to keep cash to fund operations into late 2027. | Intact | cash runs out before second half of 2027 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “The Company expects that current cash, cash equivalents and short-term investments as of June 30, 2026, will be sufficient to fund its operating expenses into the second half of 2027.” “The Company expects that current cash, cash equivalents and short-term investments as of March 31, 2026, will be sufficient to fund its operating expenses into the second half of 2027.” Operating cash flow was $-21.490 million in 2026-Q1. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative clinical-development business, not an established earnings compounder. The long-term thesis is intact, with clinical milestones progressing on schedule, but losses, high risk, and a short funding horizon keep the evidence mixed.
The valuation evidence describes ACET as cheap versus peers, with medium confidence, while the business remains loss-making. No valuation fragility flags are present, but the evidence does not specify what clinical success or failure the market assumes.
Near term, the company is expected to remain loss-making as it funds research and development; cash declined from $137.6 million in the first quarter of 2026 to $118.2 million in the second quarter. Management says cash can fund operations into the second half of 2027, while clinical milestones for prula-cel and ADI-212 remain on their stated schedules. Earnings-miss risk is elevated, and a guidance cut, weaker jobs data, or the September litigation filing could weigh on the business outlook; two recent earnings beats offer some support.
Over the next year, the thesis hinges on prula-cel clinical updates and the planned pivotal-trial startup, plus the regulatory filing and Phase 1 start for ADI-212. Timely progress would support the development case, while delays or weaker guidance would add concern as cash is used. Broader sector support may help sentiment, but weakening employment could increase pressure on cyclical healthcare names.
For the next 1 to 3 years, ACET’s long-term thesis rests on delivering clinical milestones before its stated funding horizon becomes a greater concern. The evidence is mixed, with an intact thesis but high execution and earnings risk. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Advance clinical development of allogeneic gamma delta T cell therapies | Adicet Bio focuses on developing new cancer cell therapies. | Improving | clinical development stalls or regresses in 2026 | Qualitative: FDA clearance for ADI-212 Phase 1 (Aug 2026) and Prula-cel data (Sep 2026) vs. sustained advancement target FDA cleared ADI-212 Phase 1 trial in August 2026; Prula-cel Phase 1 preliminary data released in September 2026. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Manage operating expenses to support clinical development | A supporting condition in Adicet Bio Inc's published investment case. The stated target is reduce operating loss to about -$21.57M by 2026-Q1. | Intact | operating loss worsens beyond -$21.57M in 2026-Q1 | Operating income: $-22.301M FY2026-Q2; GAAP. Published target: reduce operating loss to about -$21.57M by 2026-Q1. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 5, 2026-22,301,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “Financial Results for Second Quarter 2026: • Research and Development (R&D) expenses were $18.5 million for the three months ended June 30, 2026.” “Financial Results for First Quarter 2026: Three months ended March 31, 2026 • Research and Development (R&D) Expenses: R&D expenses were $17.5 million for the three months ended March 31, 2026, compared to $22.8 million during the same period in 2025.” Revenue was $1.168 million in 2026-Q2. Delivery assessment Nov 4, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-4.19 → $-4.04 · observed estimates
$0.03B → $0.03B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-4.19 | $34,226,400 | 5 / 5 |
| 2026-07-25 | $-3.49 | $42,783,000 | 4 / 4 |
| 2026-07-26 | $-3.49 | $42,783,000 | 4 / 4 |
| 2026-07-27 | $-3.49 | $42,783,000 | 4 / 4 |
| 2026-07-28 | $-3.67 | $34,220,000 | 3 / 4 |
| 2026-07-29 | $-3.49 | $42,783,000 | 4 / 4 |
| 2026-07-30 | $-3.49 | $42,783,000 | 4 / 4 |
| 2026-07-31 | $-3.67 | $34,220,000 | 3 / 4 |
| 2026-08-01 | $-3.49 | $42,783,000 | 4 / 4 |
| 2026-08-02 | $-3.49 | $42,783,000 | 4 / 4 |
| 2026-08-03 | $-3.49 | $42,783,000 | 4 / 4 |
| 2026-08-04 | $-3.49 | $42,783,000 | 4 / 4 |
| 2026-08-05 | $-3.49 | $42,783,000 | 4 / 4 |
| 2026-08-06 | $-3.67 | $34,226,420 | 3 / 4 |
| 2026-08-07 | $-3.49 | $42,783,000 | 4 / 4 |
| 2026-08-08 | $-4.38 | $0 | 3 / 1 |
| 2026-08-09 | $-4.38 | $0 | 3 / 1 |
| 2026-08-10 | $-4.38 | $0 | 3 / 1 |
| 2026-08-11 | $-3.02 | $42,783,000 | 4 / 4 |
| 2026-08-12 | $-3.02 | $42,783,000 | 4 / 4 |
| 2026-08-13 | $-3.02 | $42,783,000 | 4 / 4 |
| 2026-08-14 | $-3.30 | $34,226,420 | 3 / 4 |
| 2026-08-15 | $-3.30 | $34,226,420 | 3 / 4 |
| 2026-08-16 | $-3.30 | $34,226,420 | 3 / 4 |
| 2026-08-17 | $-3.30 | $34,226,420 | 3 / 4 |
| 2026-08-18 | $-3.30 | $34,226,420 | 3 / 4 |
| 2026-08-19 | $-3.30 | $34,226,420 | 3 / 4 |
| 2026-08-20 | $-3.30 | $34,226,420 | 3 / 4 |
| 2026-08-21 | $-4.03 | $28,522,017 | 4 / 5 |
| 2026-08-22 | $-4.03 | $28,522,017 | 4 / 5 |
| 2026-08-23 | $-4.03 | $28,522,017 | 4 / 5 |
| 2026-08-24 | $-4.03 | $28,522,017 | 4 / 5 |
| 2026-08-25 | $-4.03 | $28,522,017 | 4 / 5 |
| 2026-08-26 | $-4.03 | $28,522,017 | 4 / 5 |
| 2026-08-27 | $-4.03 | $28,522,017 | 4 / 5 |
| 2026-08-28 | $-4.03 | $28,522,017 | 4 / 5 |
| 2026-08-29 | $-4.08 | $28,522,000 | 4 / 5 |
| 2026-08-30 | $-4.08 | $28,522,000 | 4 / 5 |
| 2026-08-31 | $-4.08 | $28,522,000 | 4 / 5 |
| 2026-09-01 | $-4.08 | $28,522,000 | 4 / 5 |
| 2026-09-02 | $-4.08 | $28,522,000 | 4 / 5 |
| 2026-09-03 | $-4.08 | $28,516,667 | 4 / 6 |
| 2026-09-04 | $-4.08 | $28,516,667 | 4 / 6 |
| 2026-09-05 | $-4.08 | $28,516,667 | 4 / 6 |
| 2026-09-06 | $-4.08 | $28,516,667 | 4 / 6 |
| 2026-09-07 | $-4.08 | $28,516,667 | 4 / 6 |
| 2026-09-08 | $-4.08 | $28,516,667 | 4 / 6 |
| 2026-09-09 | $-4.08 | $28,516,667 | 4 / 6 |
| 2026-09-10 | $-4.08 | $28,516,667 | 4 / 6 |
| 2026-09-11 | $-4.08 | $28,516,667 | 4 / 6 |
| 2026-09-12 | $-4.08 | $28,522,000 | 4 / 6 |
| 2026-09-13 | $-4.08 | $28,522,000 | 4 / 6 |
| 2026-09-14 | $-4.08 | $28,522,000 | 4 / 6 |
| 2026-09-15 | $-4.08 | $28,522,000 | 4 / 6 |
| 2026-09-16 | $-4.08 | $28,522,000 | 4 / 6 |
| 2026-09-17 | $-4.08 | $28,522,000 | 4 / 6 |
| 2026-09-18 | $-4.08 | $28,522,000 | 4 / 6 |
| 2026-09-19 | $-4.08 | $28,516,667 | 4 / 6 |
| 2026-09-20 | $-4.08 | $28,516,667 | 4 / 6 |
| 2026-09-21 | $-4.08 | $28,516,667 | 4 / 6 |
| 2026-09-22 | $-4.08 | $28,516,667 | 4 / 6 |
| 2026-09-23 | $-4.08 | $28,516,667 | 4 / 6 |
| 2026-09-24 | $-4.08 | $28,516,667 | 4 / 6 |
| 2026-09-25 | $-4.08 | $28,516,667 | 4 / 6 |
| 2026-09-26 | $-4.08 | $28,516,667 | 4 / 6 |
| 2026-09-27 | $-4.08 | $28,516,667 | 4 / 6 |
| 2026-09-28 | $-4.08 | $28,516,667 | 4 / 6 |
| 2026-09-29 | $-4.04 | $28,516,667 | 4 / 6 |
| 2026-09-30 | $-4.04 | $28,516,667 | 4 / 6 |
| 2026-10-01 | $-4.04 | $28,516,667 | 4 / 6 |
| 2026-10-02 | $-4.04 | $28,516,667 | 4 / 6 |
| 2026-10-03 | $-4.04 | $28,516,667 | 4 / 6 |
| 2026-10-04 | $-4.04 | $28,516,667 | 4 / 6 |
| 2026-10-05 | $-4.04 | $28,516,667 | 4 / 6 |
| 2026-10-06 | $-4.04 | $28,516,667 | 4 / 6 |
| 2026-10-07 | $-4.04 | $28,516,667 | 4 / 6 |
| 2026-10-08 | $-4.04 | $28,516,667 | 4 / 6 |
| 2026-10-09 | $-4.04 | $28,516,667 | 4 / 6 |
| 2026-10-10 | $-4.04 | $28,516,667 | 4 / 6 |
| 2026-10-11 | $-4.04 | $28,516,667 | 4 / 6 |
| 2026-10-12 | $-4.04 | $28,516,667 | 4 / 6 |
| 2026-10-13 | $-4.04 | $28,516,667 | 4 / 6 |
| 2026-10-14 | $-4.04 | $28,516,667 | 4 / 6 |
| 2026-10-15 | $-4.04 | $28,516,667 | 4 / 6 |
| 2026-10-16 | $-4.04 | $28,516,667 | 4 / 6 |
| 2026-10-17 | $-4.04 | $28,516,667 | 4 / 6 |
| 2026-10-18 | $-4.04 | $28,516,667 | 4 / 6 |
| 2026-10-19 | $-4.04 | $28,516,667 | 4 / 6 |
| 2026-10-20 | $-4.04 | $28,516,667 | 4 / 6 |
| 2026-10-21 | $-4.04 | $28,516,667 | 4 / 6 |
| 2026-10-22 | $-4.04 | $28,516,667 | 4 / 6 |
| 2026-10-23 | $-4.04 | $28,516,667 | 4 / 6 |
| 2026-10-24 | $-4.04 | $28,516,667 | 4 / 6 |
| 2026-10-25 | $-4.04 | $28,516,667 | 4 / 6 |
| 2026-10-26 | $-4.04 | $28,516,667 | 4 / 6 |
| 2026-10-27 | $-4.04 | $28,516,667 | 4 / 6 |
| 2026-10-28 | $-4.04 | $28,516,667 | 4 / 6 |
| 2026-10-29 | $-4.04 | $28,516,667 | 4 / 6 |
| 2026-10-30 | $-4.04 | $28,516,667 | 4 / 6 |
| 2026-10-31 | $-4.04 | $28,516,667 | 4 / 6 |
| 2026-11-01 | $-4.04 | $28,516,667 | 4 / 6 |
| 2026-11-02 | $-4.04 | $28,516,667 | 4 / 6 |
| 2026-11-03 | $-4.04 | $28,516,667 | 4 / 6 |
| 2026-11-04 | $-4.04 | $28,516,667 | 4 / 6 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 6 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.